US Patent Issued to Dana-Farber Cancer Institute on Jan. 27 for "Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9" (Massachusetts, New Hampshire Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,501, issued on Jan. 27, was assigned to Dana-Farber Cancer Institute Inc. (Boston).

"Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9" was invented by Loren D. Walensky (Newton, Mass.), Ruben Carrasco (Brookline, Mass.) and Gregory H. Bird (Pelham, N.H.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provide...